---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Diazoxide"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Diazoxide. Topics: First-line medical therapy for advanced insulinoma: ENETS guidance, Diazoxide in metastatic insulinoma: ESMO guideline, Preoperative control of insulinoma hypoglycemia with diazoxide: NANETS surgical guideline, Dosing and adverse effects of diazoxide in insulinoma: clinical review, and 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/diazoxide"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Diazoxide

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Diazoxide

<a id="topic-2.2.2.1.4-1"></a>

### First-line medical therapy for advanced insulinoma: ENETS guidance

> “First-line medical therapy for advanced insulinoma consists of diazoxide (50–600 mg daily).”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.4-2"></a>

### Diazoxide in metastatic insulinoma: ESMO guideline

> “Diazoxide is of value in metastatic insulinoma, as it inhibits the secretion of insulin by tumour cells”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.4-3"></a>

### Preoperative control of insulinoma hypoglycemia with diazoxide: NANETS surgical guideline

> “Treatment of insulinoma relies on dietary changes as well as pharmacotherapy with diazoxide that can control hypoglycemia in 50–60% of cases.”

Source: [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/)

<a id="topic-2.2.2.1.4-4"></a>

### Dosing and adverse effects of diazoxide in insulinoma: clinical review

> “Diazoxide is a nondiuretic benzothiadiazide vasodilator also known to control insulin secretion by blocking the adenosine triphosphate-dependent potassium channels of the pancreatic β cells (75).”
> “Generally, doses between 300 and 900 mg per day, usually divided into 3 equal and increasing doses every 8 hours, are rapidly successful in reversing hypoglycemia. The most frequent dose-limiting side effects of diazoxide occurring in up to 80% are fluid retention and edema, palpitations, nausea, anorexia, and hirsutism in female patients. Combination with a thiazide diuretic is generally recommended to prevent fluid retention, edema, and severe weight gain (7, 70, 78–80).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.4-5"></a>

### Indication, dosing, warnings, and adverse reactions: diazoxide prescribing information

> “PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: • Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.”
> “PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.”
> “When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered.”
> “Adults and children: The recommended starting dosage is 3 mg/kg/day, administered orally, divided into 3 equal doses every 8 hours or 2 equal doses every 12 hours. The dosage may be titrated to a maximum of 8 mg/kg/day. Patients with refractory hypoglycemia may require higher dosages.”
> “If administration of PROGLYCEM is not effective after 2 or 3 weeks, discontinue PROGLYCEM.”
> “The antidiuretic property of diazoxide may lead to significant fluid retention. In patients with compromised cardiac reserve, fluid retention may precipitate congestive heart failure.”
> “Ketoacidosis and nonketotic hyperosmolar coma have been reported in patients treated with PROGLYCEM, usually during intercurrent illness.”
> “Hirsutism of the lanugo type, mainly on the forehead, back and limbs, occurs most commonly in children and women and may be cosmetically unacceptable.”
> “Thrombocytopenia with or without purpura may require discontinuation of PROGLYCEM.”

Source: [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### Long-term diazoxide in 40 patients with insulinoma: national survey

> “A survey of UK patients receiving the drug diazoxide, revealed 40 patients with insulinoma on this treatment.”
> “Duration of treatment was 7 +/- 6 years (range 1-22). Most (55%) patients were treated with diazoxide because of tumour non-localisation (including failed previous surgery). Metastatic disease (20%) and poor surgical risk (10%) were other indications. Side-effects (notably fluid retention and hirsutism) were common (47%) but not troublesome. Treatment was highly effective--59% were symptom free and 38% had only occasional symptoms. Only one patient had frequent hypoglycaemia despite treatment.”

Source: [Gill et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431498/)

<a id="topic-2.2.2.1.4-7"></a>

### Diazoxide response and adverse effects in 20 patients with insulinoma

> “We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases.”
> “Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma.”
> “Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide.”

Source: [Niitsu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30504655/)

<a id="topic-2.2.2.1.4-8"></a>

### Edema and heart failure with diazoxide in inoperable insulinoma

> “Herein, we report the results of our retrospective clinical record review of 6 Japanese patients (3 females and 3 males, ranging in age from 58 to 91 years) with hyperinsulinemic hypoglycemia and inoperable insulinoma treated with diazoxide. Diazoxide improved control of hypoglycemic symptoms and maintained normoglycemia in 5 of the 6 patients, and was ineffective in one patient. Surprisingly, although all 6 patients received diazoxide according to the treatment strategy recommended in Western patients, 5 of the 6 patients developed edema and two developed congestive heart failure.”

Source: [Komatsu et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26598136/)

<a id="topic-2.2.2.1.4-9"></a>

### Diazoxide in NICTH: clinical review

> “Diazoxide and octreotide have no role in NICTH.”
> “Use in NICTH was not found to be successful in any case we reviewed (33, 36, 41, 53, 90). Additionally, use is often limited by fluid retention and edema (41).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.4-10"></a>

### Diazoxide among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- | --- |
| Diazoxide | “16 (6.9%)” | “10 (5.8%)” | “6 (11.8%)” | “.25” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Halfdanarson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32675783/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
